Robert Langreth

UniQure NV slumped in early trading after reporting that the benefits of its Huntington’s disease gene therapy drug AMT-130 were not as good after four years as they were after three years in a small trial — a result that could complicate its bid to get the treatment approved by US regulators.

Johnson & Johnson raised its profit guidance as demand for newer drugs in cancer and autoimmune diseases overshadowed more anemic growth in the company’s medical device business.

The US Food and Drug Administration is kicking off a top-to-bottom review of how it approaches rare disease drug development and approvals.

Revolution Medicines Inc.’s pancreatic cancer drug won the backing of a key European Union advisory panel, the company said in a statement Thursday, moving the life-extending medicine closer to reaching patients in the 27-nation bloc.

Shares in Tempus AI fell after data on Moderna and Merck’s widely anticipated personalized melanoma vaccine disappointed Wall Street.

Leaked data from Moderna Inc. and Merck & Co.’s highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks.

Leaked data from Moderna Inc. and Merck & Co.'s highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks.

Leaked data from Moderna Inc. and Merck & Co.'s highly anticipated melanoma vaccine trial has led to a rare disconnect between doctors, who celebrated the result, and Wall Street, which sold off the stocks.

Moderna Inc. Chief Executive Officer Stephane Bancel said he believes the personalized mRNA cancer vaccine his company is developing with Merck & Co. will work in a variety of tumors, directly addressing a key issue shrouding the company’s future.